Quest Diagnostics' Q2 2026 Earnings Surpass Expectations; Full-Year Guidance Raised

Quest Diagnostics’ Q2 2026 Earnings Surpass Expectations; Full-Year Guidance Raised

Quest Diagnostics Incorporated (NYSE: DGX) has reported robust financial results for the second quarter of 2026, exceeding analyst expectations and prompting an upward revision of its full-year guidance.

Strong Financial Performance in Q2 2026

In the quarter ending June 30, 2026, Quest Diagnostics achieved revenues of $3.04 billion, marking a 10.2% increase compared to the same period in 2025. This growth was primarily driven by a 13.1% rise in testing demand, with organic requisition volume contributing 13.0% to this uptick.

The company’s adjusted earnings per share (EPS) stood at $3.12, reflecting a 19.1% year-over-year increase and surpassing the Zacks Consensus Estimate by 11%. On a GAAP basis, EPS was reported at $2.84, up 15% from the prior year.

Diagnostic Information Services Drive Growth

The Diagnostic Information Services segment, which accounts for nearly all of Quest’s consolidated revenues, reported revenues of $2.98 billion, a 10.3% increase from the previous year. This growth was bolstered by increased demand across physician, hospital, and consumer channels.

Upward Revision of Full-Year 2026 Guidance

Buoyed by the strong quarterly performance, Quest Diagnostics has raised its full-year 2026 guidance. The company now anticipates revenues between $11.70 billion and $11.82 billion. Adjusted diluted EPS is projected to be in the range of $10.50 to $10.70, up from the previous estimate of $10.30 to $10.50.

Market Response and Analyst Outlook

Following the earnings announcement, Quest Diagnostics’ stock experienced a positive movement. As of July 27, 2026, DGX shares were trading at $231.84, reflecting a 2.61% increase from the previous close.

Analysts have responded favorably to the company’s performance. Baird raised its price target for DGX to $236 from $232, maintaining a Neutral rating. This adjustment reflects confidence in Quest’s ability to sustain growth and deliver value to shareholders.

Conclusion

Quest Diagnostics’ impressive second-quarter results and the subsequent upward revision of its full-year guidance underscore the company’s strong position in the diagnostic information services sector. Investors and stakeholders will be closely monitoring Quest’s performance in the coming quarters to assess its ability to maintain this growth trajectory.